VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback